ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, has today announced analysis of the results from the open label six month extension study from its original Pivotal Phase..

ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company, has today announced that it has entered into a subscription agreement with Lanstead Capital Investors LP, an institutional investor,..

ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company, has today announced its final results for the twelve months ended 31 December 2018. Key Highlights (including post Period..

ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company has today provided the following update on ongoing activities. Lupuzor™ Lupuzor™ is the Company’s late stage asset for Lupus,..

ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company provides an update in relation to its discussions with Incanthera Limited on its Nucant cancer programme. Background On 7..

ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company provided today an update on ongoing activities. Key highlights: · Lupuzor™ o Lupuzor™ ‘Managed Access Program’ o Phase III..

ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company has today announced that on 25 February 2019, the peer reviewed research journal ‘Nature Communications’ published a fundamental scientific..

ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company today provides an update on its clinical development collaboration agreement for its Nucant cancer programme, with Incanthera Limited, a..

ImmuPharma PLC (LON: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited as the Company’s Nominated Advisor, with immediate effect...

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company has today provided an update on its ongoing activities. Key highlights: · Lupuzor™ o Lupuzor™ ‘Managed Access Programme’ o..

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced its interim results for the six months ended 30 June 2018. Key Highlights LupuzorTM · Lupuzor™ demonstrated..

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, have today announced that it has, with immediate effect, appointed Stanford Capital Partners and SI Capital as joint brokers. They..

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company today announced a corporate update. Key highlights: · Lupuzor™ o Agreement signed to enter Lupuzor™ into a ‘Managed Access Programme’..

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today provided insight into its positive results from pre-clinical studies of the P140 peptide for Chronic Inflammatory Demyelinating Polyneuropathy..

ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced further analysis of the results from its pivotal Phase III trial of Lupuzor™, its lead programme for..